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Abstract
Introduction: Androgen receptor (AR) gene mutations are the most frequent cause of 46,XY disorders of sex development (DSD), and 
are associated with a variety of phenotypes ranging from phenotypic women (Complete Androgen Insensitivity Syndrome or CAIS) 
to milder degrees of undervirilisation (Partial Androgen Insensitivity Syndrome or PAIS) or men with infertility only (Mild Androgen 
Insensitivity Syndrome or MAIS).
In this paper, we present the results of clinical, endocrine and molecular trials in a patient hospitalised because of primary amenorrhoea 
with typical phenotype of CAIS.
Material and methods: The main objective of this study was to determine the molecular cause of androgen insensitivity syndrome in 
a 46,XY female patient. Molecular analysis of the AR gene was conducted using MSSCP (Multitemperature Single Strand Conformation 
Polymorphism) and sequencing methods.
Results: MSSCP analysis showed changes in electrophoretic mobility in exon 8 of the AR gene. Sequencing analysis revealed a missense 
mutation which has not been previously described. This is a c.T3816 > C transition mutation which causes a S901P substitution in the 
amino acid chain (based on the latest NCBI reference sequence NM 000044.2). 
Conclusions: The identified c.T3816 > C mutation in AR gene provides further evidence for the correlation between specific AR mutations 
and phenotype corresponding to androgen insensitivity. (Endokrynol Pol 2013; 64 (5): 398–402)
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Streszczenie
Wstęp: Mutacje w genie receptora androgenowego (AR, Androgen Receptor) są najczęstszą przyczyną zaburzeń różnicowania płci (DSD, 
Disorders of Sex Development) powodującą zespół niewrażliwości na androgeny (AIS, Androgen Insensitivity Syndrome). Chorzy wykazują 
znaczną różnorodność fenotypu: od żeńskiego (CAIS, Complete Androgen Insensitivity syndrome) przez niecałkowicie męski (PAIS, Partial 
Androgen Insensitivity Syndrome) aż do prawidłowo zbudowanych niepłodnych mężczyzn (MAIS, Mild Androgen Insensitivity Syndrome).
W pracy przedstawiamy wyniki badań klinicznych, endokrynologicznych oraz molekularnych pacjentki hospitalizowanej z powodu 
pierwotnego braku miesiączki z typowymi cechami zespołu niewrażliwości na androgeny.
Materiał i metody: Celem badań było określenie podłoża molekularnego zespołu niewrażliwości na androgeny u kobiety 46,XY. Prze-
prowadzono analizę molekularną genu AR z zastosowaniem metod: MSSCP (Multitemperature Single Strand Conformation Polymorphism) 
oraz sekwencjonowania.
Wyniki: Analiza polimorfizmu konformacji pojedynczych nici DNA w gradiencie temperatury wykazała zmianę ruchliwości elektrofo-
retycznej w egzonie 8 genu AR. W wyniku sekwencjonowania egzonu 8 wykryto mutację punktową typu missens. Mutacja, dotychczas 
nie opisywana, ma charakter tranzycji c.T3816 > C i powoduje zmianę S901P w łańcuchu aminokwasowym (w oparciu o najnowszą 
sekwencję referencyjną NCBI, NM 000044.2). 
Wnioski: Stwierdzenie nowej mutacji, c.T3816 > C w genie AR jest kolejnym dowodem potwierdzającym związek mutacji AR z fenotypem 
zespołu niewrażliwości na androgeny. (Endokrynol Pol 2013; 64 (5): 398–402)
Słowa kluczowe: zaburzenia rozwoju płci, zespół niewrażliwości na androgeny, receptor androgenowy, mutacja missens
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Introduction
Androgen receptor (AR) gene mutations are the most 
frequent cause of 46,XY disorders of sex development 
(DSD), and are associated with a variety of phenotypes, 
ranging from phenotypic women (CAIS) to milder 
degrees of undervirilisation (PAIS) or men with only 
infertility (MAIS) [1–3].
The androgen receptor is an intracellular receptor 
ligand that functions as a transcription factor. The pro-
tein is composed of four different functional domains 
responsible for gene transactivation (NTD, N-terminal 
domain), DNA binding (DBD, DNA-binding domain), 
receptor transport to the nucleus and hormone binding 
(LBD, C-terminal ligand-binding domain)[4]. The AR 
has two main activation functions: constitutive (AF-1) 
in NTD, and hormone-dependent (AF-2) in the LBD. 
AR AF-2 interactions with the AR-NTD (AR N/C termi-
nal interactions) are essential for the transactivational 
properties of the receptor [5].
The gene encoding the androgen receptor is local-
ised in region q11-12 of the X chromosome. It consists 
of eight exons. Exon 1 encodes the NTD domain, 
exons 2 and 3 encode the DBD domain, exons 3 and 
4 encode hinge region or bipartite nuclear localisa-
tion, and exons 4–8 encode the LBD domain [6]. More 
than 800 different mutations in the AR gene have 
been identified in people with androgen insensitiv-
ity syndrome and most AR mutations are localised in 
the LBD and are available in the mutations database 
[1, 7]. The steroid-binding domain contains residues 
between amino acids 670 and 919 of the AR and is 
encoded by a part of exon 4 and exons 5–8. The re-
gion shares 50% homology with respective regions 
of other steroid receptors. Its crystal structure shows 
that the LBD consists of nine a-helices, two 310 helices, 
described as helices 1–12, and four short b-strands 
and two antiparallel b-sheets. The main function of 
this domain is highly specific binding of androgens. 
The correct structure is needed to convert an inactive 
form to an active one of the receptor upon binding of 
androgens. It is also involved in receptor dimerisation 
and transcriptional regulation [8, 9].
LBD mutations include a majority of amino acid 
residues that line the AR ligand-binding pocket [10]. 
However, many other mutations may have an indi-
rect impact on the structure of the cofactor-binding 
pocket and binding of the ligand. Disrupted bind-
ing of the ligand may also affect the structure of the 
cofactor-binding groove, and inhibit N/C and cofac-
tor interaction. Furthermore, binding of proteins to 
the cofactor-binding groove might affect binding 
of the ligand [11]. There is evidence indicating that 
disrupted N/C interaction can serve as a mechanism 
for AIS also in cases where ligand binding is normal 
[12–14].
Mutations of this domain lead to AR disorders 
responsible for androgen insensitivity syndrome or 
contribute to an increased risk of the development of 
prostate cancer [15, 16].
In this study, we describe a 46,XY phenotypically 
female patient with all of the characteristics of CAIS in 
which a novel mutation in exon 8 of the AR gene in the 
LBD domain is responsible for the disease.
Case description and methods
The patient was referred to the Genetic Outpatients 
Clinic at the age of 21 due to primary amenorrhoea. The 
patient’s height was 171 cm; delayed puberty: A-0, P-0, 
Th-1, amenorrhoea, normal structure of external sexual 
organs was found on physical examination. Family 
history: two younger sisters of the patient menstruate 
normally, however primary amenorrhoea in a daughter 
of one of the mother’s sisters was observed. We did not 
have the possibility to perform the test.
The gynaecological examination confirmed female 
external sexual organs: no pubic and axillary hair, labia 
majora underdevelopment, labia minora normal. Clito-
ris not enlarged with normal structure. Vaginal recess 
ca. 3 cm. long, blind-ended. Hormonal studies showed 
high testosterone level, low gonadotropin levels and 
oestradiol within the normal female ranges. Cytoge-
netic examination revealed a 46,XY karyotype both in 
lymphocytes and skin fibroblasts. The material derived 
from skin biopsy was cultured in situ for archiving the 
patient’s cells in the tissue bank. The patient remained 
under medical supervision of the Genetic Outpatients 
Clinic; however, surgery was not performed despite 
recommended gonadectomy due to lack of patient 
consent for the treatment.
Ultrasound examination of the pelvis revealed an 
oval hypoechogenic cyst (30 x 16 mm) in the left ingui-
nal area within the true pelvis, and a non-homogenous 
double cystic structure in the right inguinal area. CT 
examination of the pelvis: an oval, solid structure, 3–2.8 
cm, visible medially from the vascular bundle in the left 
inguinal area. No uterus in the minor pelvis. Ultrasound 
test result was one of the arguments for carrying out 
diagnostic laparoscopy.
Physical examination of the patient at the age of 
30 revealed puberty stages: A-0, P-1, Th-III; palpation 
and ultrasound examinations confirmed the presence 
of a dysplastic gonad within the left inguinal canal. 
Gonadectomy was recommended again. The patient 
underwent gonadectomy at the age of 34 (Fig. 1AB).
Histopathological examination of the gonads: both 
gonads have similar histopathological structures with 
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prevailing Sertoli cell nodules and benign Sertoli cell 
tumours with single gonocytes. They are separated by 
a hyalinised stroma with scarce Leydig cells in intertu-
bular spaces. Hyaline bodies are visible in the tubular 
lumens of either gonad. The microscopic picture on the 
left side reveals some texture of the uterine tube with 
extended lumen and wall fibrosis. Malignancy of the 
tumours was not found. The WHO recommendations, 
suggesting a differentiation between Sertoli cell nod-
ules and Sertoli cell tumours, turned out to be totally 
impractical (Fig. 1CD).
Molecular analysis
Genomic DNA of the patient and a healthy person 
(control) was automatically isolated from peripheral 
blood lymphocytes (MagNa Pure Compact, Roche).
Exons from 2 to 8 of the AR gene were amplified with 
PCR using specific primers [17]. PCR products were 
screened with the MSSCP method and/or direct se-
quencing (Macrogen’s sequencing service, Korea).
Results and discussion
Clinical and histopathological findings and diag-
nostic laparotomy was carried out in the framework 
of  the differential diagnostics of CAIS. Results of 
molecular analysis decisively confirmed the prelimi-
nary diagnosis.
Single strand conformation polymorphism analysis 
of the PCR products of the AR gene revealed changes 
in electrophoretic mobility in exon 8, which could sug-
gest the occurrence of a mutation. Sequencing of exon 
8 confirmed a missense mutation in position c.T3816 
> C. This transition mutation results in a change of 
serine into proline at position 901 of the amino acid 
chain (S901P) (Fig. 2AB). This mutation has not been 
previously described in the literature.
The mutation is localised in the LBD domain of 
the AR within helix 12 of the AF-2 core domain. In 
line with the crystal structure of the AR, Ser 901 is the 
last amino acid residue of the AF-2 core domain of 
the activation domain (AD) located in helix 12 in the 
Figure 1. Gonadectomy and gonadal histopathology: A, C. right gonad; B, D. left gonad
Rycina 1. Gonadektomia i histopatologia gonad: A, C. gonada prawa; B, D. gonada lewa
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C-terminal end of the LBD [18]. This short C-terminal 
sequence is conserved in the family of nuclear recep-
tors and is essential for their normal functioning. To 
investigate the role of Ser 901 in AR LBD structure, we 
used a three-dimensional model of human androgen 
receptor ligand binding domain. This was generated 
on the basis of the known atomic structure of AR LBD 
available from Protein Data Bank with accession code 
1e3g [19]. The model of androgen receptor mutant 
structure was generated by modifying the AR LBD at 
the position where the mutation occurred. The stereo 
representation was rendered and final figures were 
drawn with Swiss –PdbViewer program v 4.0.1.
S901 residue is highly conserved in the structure 
of androgen receptors among species. This residue is 
located in the loop between two a-helices and forms 
a bridge with one of these two secondary structures 
of AR LBD.
In wild type of AR LBD (Fig. 2C) the Ser901 residue 
forms two strong hydrogen bonds (green dotted line) 
with alanine (Ala897 — pink colour) and one strong 
hydrogen bond with glutamic acid (Glu898 — yellow 
colour) of one a-helix secondary structure (light-blue 
colour). Both Ala897 and Glu898 residues are conserved 
among AR LBD sequences. This pattern of Ala897-
Glu898-Ser901 conservation and hydrogen bonds 
formation suggests that the conformation of protein 
fold in this region is crucial for ligand binding domain 
stability and activity.
In the case of S901P substitution in mutant AR LBD 
(Fig. 2D), there is only one hydrogen bond with alanine 
(Ala897 — pink colour) of a-helix secondary structure 
(light-blue colour) and no hydrogen bond with glu-
tamic acid (Glu898). Additionally, substitution of serine 
by proline at 901 position leads to a steric clash (black 
dotted line) that violates basic atomic properties. The 
bond energy of the misfolded protein at this position 
is not at a minimum. The possible result is a misfold-
ing of the ligand binding domain and thus diminished 
binding affinity.
Figure 2. DNA sequence of exon 8 of the AR gene. A. c. T3816 > C mutation; B. normal sequence (control). A three-dimensional model 
of human androgen receptor ligand binding domain (with Swiss — PdbViewer program v 4.0.1): C. wildtype, B. mutant
Rycina 2. Sekwencja egzonu 8 genu AR. A. mutacja c. T3816 > C; B. sekwencja prawidłowa (kontrola). Struktura przestrzenna 
domeny LBD (w oparciu o program Swiss — PdbViewer v 4.0.1): C. struktura prawidłowa, B. mutacja c. T3816 > C
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It has been shown that the AF-2 AD plays an impor-
tant role in the N/C interaction. Disrupted binding of 
the ligand may also affect the structure of the cofactor-
binding groove and inhibit N/C interaction and cofactor 
interaction [20, 21]. 
The diagnosis of complete androgen insensitivity 
syndrome is an indication for prophylactic removal of 
the gonad because of increased risk of cancer. However, 
the issue of gonadectomy is controversial. Optimal 
timing and necessity for removal of testes have been 
debated. Some have argued that the true risk for ma-
lignant transformation of the gonads is small and have 
suggested postpubertal gonad biopsy as opposed to 
removal [22].
Histopathological examination of gonads in our pa-
tient revealed hyperplasia of Sertoli cells in the form of 
nodules (target Sertoli nodule) and/or benign tumours 
of the Sertoli cells (Sertoli cell tumour). Malignancy of 
the tumours was not found. This is consistent with the 
opinion among physicians that the risk of malignancy in 
androgen receptor insensitivity syndrome is consider-
ably lower than with other intersex disorders, and can 
occur at a later age [23, 24].
The identified mutation in AR gene is novel and 
provides further evidence for the correlation between 
specific AR mutations and phenotype corresponding 
to androgen insensitivity syndrome.
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